T he tolerogenic pathway of L-tryptophan catabolism has been implicated, with either protective or disease-promoting roles, in a variety of physiopathologic conditions, ranging from pregnancy (1) to transplantation (2) , and from autoimmunity (3) and inflammation (4 -6) to infection (7) and neoplasia (8, 9) . There is growing evidence that tryptophan catabolism may be involved in the development of depressive-like behaviors in both humans and mice (10, 11) . In the experimental models of immune regulation, a central role for IDO has been established either by using the competitive enzyme inhibitor 1-methyl-tryptophan (1-MT) 3 under in vivo or in vitro conditions or by using dendritic cells (DCs) ex vivo from IDO-deficient mice (12) . However, pharmacologic or genetic inhibition of IDO activity may not be completely informative, because IDO could not be the only relevant target of 1-MT (13) , and IDO-deficient mice, which are genetically altered hosts, might have abnormal development or differentiation of their DC lineage. Interestingly, these animals manifest compensatory or redundant mechanisms for tolerogenesis in vivo (14) . Also relevant in this regard is the recent and rather puzzling finding that the D-isomer of 1-MT is apparently more effective at inhibiting tryptophan catabolism than the universally used mixture of D,L-stereoisomers (15, 16) , in which the L-isomer is expected to be the active form of the inhibitor (13) .
Two major theories have been proposed to account for tolerance induction via tryptophan catabolism. One theory posits that tryptophan breakdown suppresses T cell proliferation by critically reducing the availability of this indispensable amino acid in local tissue microenvironments (17) . The other theory assumes that downstream metabolites of tryptophan catabolism, collectively known as kynurenines, act to suppress immune reactivity, probably through direct interactions with effector T lymphocytes and other cell types (10) . These are not mutually exclusive possibilities, and each might have a role in the immunobiology of IDO (16) , including unique actions by specific kynurenines such as 3-hydroxyanthranilic acid (3-HAA) (18) and the downstream product quinolinic acid (QUIN) (19) . Clarification of the relative contributions of the different mechanisms would be crucial to an improved understanding of the complex role of tryptophan catabolism in health and disease and to the implementation of immunotherapies targeting IDO function (13) .
IDO activity is regulated at both transcriptional and posttranslational levels (20) , and IFN-␥ represents the principal regulator of Indo transcription (21) . We have previously shown that the default functional programs of murine splenic CD8
Ϫ and CD8 ϩ DCs in the presentation in vivo of poorly immunogenic peptides are disparate but flexible (22) . IFN-␥, however, fails to modify the default immunogenic function of CD8 Ϫ DCs, although it does potentiate the basic tolerogenic program of CD8
ϩ DCs in an IDO-dependent fashion. The cytokine, in fact, will not confer tryptophan-catabolizing activity on CD8 Ϫ DCs, although the resultant IDO protein expression is comparable in the two DC subsets (23) .
In this study, we examined the role of kynurenines that are physiologically generated downstream of the initial and rate-limiting step mediated by IDO in tryptophan degradation. In addition, in IDO-competent DCs, we compared 1-MT and Indo gene silencing for modulation of the potent tolerogenic function induced by IFN-␥ in this subset. We obtained evidence that Indo silencing in
CD8
ϩ DCs had effects comparable to pharmacologic inhibition of the enzyme. Perhaps of greater interest, initiating the kynurenine pathway in CD8 Ϫ DCs downstream of IDO led to the production of QUIN and imparted tolerogenic properties to those cells in the absence of tryptophan consumption. Thus, similar to CD8 ϩ DCs, their CD8
Ϫ counterparts are competent for the portion of the pathway that is subsequent to IDO, and can further metabolize the initial kynurenine when provided externally. This suggests that the paracrine production of kynurenines could be one mechanism whereby IDO-competent cells affect the activity of DCs in which functional IDO is blocked posttranslationally.
Materials and Methods

Mice and reagents
Female DBA/2J (H-2 d ) mice were obtained from Charles River Breeding Laboratories. Synthetic kynurenines (used in vitro at 10 or 100 M according to the experimental design) and racemic 1-MT (D,L-isomers) were purchased from Sigma-Aldrich. The kynurenine 3-monooxygenase inhibitor PNU 156561 (4,5-dichlorobenzoylalanine; synthesized in the Pharmacia and Upjohn Research Laboratories of Nerviano, Italy) has been characterized previously (24) . The P815AB peptide (amino acid sequence LPYLGWLVF) was synthesized and purified as described previously (22, 25) . All in vivo studies were performed in compliance with National and Perugia University Animal Care and Use Committee guidelines.
DC preparation, treatments, and immunization
Splenic DCs were purified by magnetic-activated sorting using CD11c MicroBeads and MidiMacs (Miltenyi Biotec), in the presence of EDTA to disrupt DC-T cell complexes. Cells were Ͼ99% CD11c ϩ , Ͼ99% MHC I-A ϩ , Ͼ98% B7-2 ϩ , Ͻ0.1% CD3 ϩ , and appeared to consist of 90 -95% CD8 Ϫ , 5-10% CD8 ϩ , and 1-5% B220 ϩ cells. DC populations were further separated into CD8
Ϫ and CD8 ϩ fractions by means of CD8␣ MicroBeads (Miltenyi Biotec) (22, 25) . The CD8 Ϫ fraction was ϳ45% CD4 ϩ and typically contained Ͻ0.5% contaminating CD8 ϩ cells. Less than 1% CD8 ϩ and Ͻ5% CD8 Ϫ DCs expressed the B220 marker, respectively (26) . DCs were exposed to 100 ng/ml IL-12 (CD8 Ϫ DCs) or 200 U/ml IFN-␥ (CD8 Ϫ or CD8 ϩ DCs) for 24 h at 37°C in the presence or absence of 4 M 1-MT (27) . For immunization, cells were washed between and after incubations before peptide loading (5 M, 2 h at 37°C), irradiation, and i.v. injection into recipient hosts. A total of 3 ϫ 10 5 IL-12-treated CD8 Ϫ DCs was injected in combination with 5% IFN-␥-treated CD8 ϩ or CD8 Ϫ DCs.
Small interfering RNA (siRNA) synthesis and transfection
The siRNA sequences specific for murine Indo (sense, 5Ј-GGGCUUCU UCCUCGUCUCUtt-3Ј; antisense, 5Ј-AGAGACGAGGAAGAAGCCCtt-3Ј) were selected, synthesized, and annealed by the manufacturer (Ambion). For transfection, siRNAs (6.7 g) in 30 l of transfection buffer (20 mM HEPES, 150 mM NaCl; pH 7.4) were pipetted into a sterile Eppendorf tube. In a separate polystyrene tube, 6.7 g of 1,2-dioleoyl-3-trimethylammonium-propane were mixed with 30 l of transfection buffer, and then both solutions were mixed gently by pipetting several times. After incubation at room temperature for 20 min, the mixture was added to 1 ml of complete medium containing 10 6 DCs and incubated for 48 h at 37°C, with or without IFN-␥ during the last 18 h of incubation. Cells were then recovered, washed, and immediately used for in vitro or in vivo experiments. Control treatment consisted of Negative Control siRNA (Ambion).
PCR analysis
RT-PCR analysis was performed (30 cycles, annealing temperature of 60°C) using sense and antisense primers, as follows: Indo sense, 5Ј-GAAGGATCCTTGAAGACCAC-3Ј; Indo antisense, 5Ј-GAAGCTGCG ATTTCCACCAA-3Ј; Sod2 sense, 5Ј-AGACCTGCCTTACGACTATG-3Ј; Sod2 antisense, 5Ј-AGCGGAATAAGGCCTGTTGT-3Ј.
Real-time PCR were run on a Chromo4 Four-Color Real-Time Detector (Bio-Rad) using specific primers as follows: Indo sense, 5Ј-GAAGGATC CTTGAAGACCAC-3Ј; Indo antisense, 5Ј-GAAGCTGCGATTTCCAC CAA-3Ј; Kynu sense, 5Ј-AAATTCCCTTGGCCTTCAAC-3Ј; Kynu antisense, 5Ј-GCGTTTGCCTACATCATGG-3Ј; Kmo sense, 5Ј-GCCTTG AAAGCCATTGGTC-3Ј; Kmo antisense, 5Ј-GCACTGTGAGTAC CCCTTCC-3Ј; Haao sense, 5Ј-ACGCCGTGTGAGAGTGAAGT-3Ј; Haao antisense, 5Ј-GTAATACCTCAGCCCATCC-3Ј. PCR products were normalized to murine Gapdh using specific primers (sense, 5Ј-GCCTTC CGTGTTCCTACCC-3Ј; antisense, 5Ј-CAGTGGGCCCTCAGATGC-3Ј).
Kynurenine and quinolinic acid measurements
These procedures, using gas chromatography with electron capture negative ionization mass spectrometry (GC/MS), have previously been described in detail (28, 29) . Briefly, 10 l of culture supernatant was diluted (1/5, v/v) in water. Fifty microliters of internal standard (100 nM 3,5-pyridinedicarboxylic acid and 200 nM homophenylalanine) were added, and proteins were precipitated with HCl (25 l, 5 N). Fatty compounds were removed by extraction with chloroform (100 l). After centrifugation (10 min, 10,000 ϫ g), 100 l of the acidic supernatant were added to a glass tube containing 50 l of 62.5 mM tetrabutylammonium hydrogen sulfate. The mixture was lyophilized and resuspended in 25 l of acetone containing 7.5% of diisopropylethylamine and 3% pentafluorobenzyl bromide. The samples were incubated in sealed tubes for 15 min at 60 -65°C. Fifty microliters of decane and 750 l of water were then added, the samples were thoroughly mixed, and the decane phase was removed. One microliter of the decane phase was injected into a GC/MS system consisting of a Trace GC coupled with a Trace MS quadrupole mass spectrometer (ThermoFinnigan). Chromatographic separation was achieved using a 30-m Rtx-5MS capillary column (0.25-mm internal diameter, 0.25-m film thickness; Restek) with helium as a carrier gas. A split/splitless injection port (1-l injection volume) was used. The temperature program was as follows: 155°C for 1.25 min, 40°C/min to 275°C, 10°C/min to 320°C, 1 min at 320°C, injection port 228°C. The GC/MS uses electron capture negative ion chemical ionization mass spectroscopy with methane as the reagent gas. The ion source temperature was 220°C. Selected ion monitoring was performed by recording signals of characteristic (M-PFB)
Ϫ ions.
Skin test assay
A skin test assay was used for measuring class I-restricted delayed-type hypersensitivity responses to synthetic peptides as described previously (22, 30, 31) . Results were expressed as the increase in footpad weight of peptide-injected footpads over that of vehicle-injected counterparts. Values (mean Ϯ SD) are compiled data from independent experiments with at least six mice per group per experiment. The statistical analysis was performed using Student's paired t test by comparing the mean weight of experimental footpads with that of control counterparts.
Induction of apoptosis by IDO ϩ DCs
Conditions for inducing and assaying IDO-dependent apoptosis have been described previously (32) . Briefly, CD8 ϩ or CD8 Ϫ DCs (2 ϫ 10 5 ), treated overnight with IFN-␥ in the presence or absence of 10 M L-kynurenine (KYN), were washed and cultured for 48 h with 4 ϫ 10 5 F76 cells, a Th1-type P815AB-specific CD4 ϩ T cell clone, in the presence of 5 M P815AB peptide. At the end of the coculture, the CD11c ϩ cells were removed by the use of CD11c MicroBeads (Miltenyi Biotec), and the remainder of the population was surface stained with anti-CD4-PE and FITC-labeled annexin V and propidium iodide (PI; BD Pharmingen). For measurement of apoptosis, a gate was set on CD4 ϩ T cells, and the percentage of cells in the very early stages of apoptosis was determined by annexin V staining excluding PI ϩ cells.
Transwell DC conditioning
DC conditioning by IDO-competent cells was performed using a 6.5-mm Transwell system (Corning) with a 0.4-m pore polycarbonate membrane insert. CD8 Ϫ DCs (10 6 ) were added to the lower chamber, while CD8
ϩ DCs (10 6 ) were added to the upper chamber. Cultures were set up in the presence of 200 U/ml IFN-␥, and, after 18 h, CD8
Ϫ DCs were recovered, extensively washed, and used for in vivo sensitization.
Results
Indo silencing and 1-MT have comparable effects on functional IDO in vitro and in vivo
IDO catalyzes the initial and rate-limiting step in tryptophan degradation to QUIN through the sequential formation of KYN, 3-hydroxykynurenine (3-HK) or alternatively anthranilic acid (AA), and 3-HAA (Fig. 1) . Thus, pharmacologic blockade of IDO by the use of 1-MT results in impaired formation of KYN and the downstream metabolites including QUIN. siRNA technology is a means of posttranscriptional gene silencing that can be used to modulate gene expression in murine DCs (25, 27) . To comparatively examine the effects of 1-MT and posttranscriptional Indo silencing, splenic DCs were fractionated and the CD8 ϩ fraction, treated or not with IFN-␥, was transfected with Indo-specific or control siRNA, resulting in efficient and selective inhibition of Indo transcript expression at 48 h of transfection ( Fig. 2A) . This was accompanied by inhibition of IDO function as measured by the production of KYN by IFN-␥-treated CD8
ϩ DCs (Fig. 2B) as well as by their ability to induce apoptosis of a Th1 clone, as documented previously (32, 33) (Fig. 2C) . All of these functional effects in vitro were mimicked by the use of 1-MT in place of Indo siRNA.
DC populations in the spleens of DBA/2 mice consist of CD8 Ϫ (ϳ90%) and CD8 ϩ (ϳ10%) fractions that mediate the respective immunogenic and tolerogenic presentation of the synthetic tumor/ self nonapeptide P815AB. Upon transfer into recipient hosts, peptide-loaded CD8 Ϫ DCs initiate immunity, and CD8 ϩ DCs initiate anergy, when Ag-specific skin test reactivity is measured at 2 wk after cell transfer (30, 31) . On cotransferring cytokine-conditioned DCs of the two subsets, the IDO-inducing tolerogenic potential of IFN-␥ acting on CD8
ϩ DCs enables these cells to prevail over the adjuvant properties of IL-12 acting on CD8 Ϫ DCs, resulting in lack of skin test reactivity (22, 34 -36) . P815AB-pulsed, IL-12-treated CD8
Ϫ DCs were injected in combination with 5% CD8 ϩ DCs, either untreated or treated with IFN-␥, with or without concomitant 1-MT or Indo siRNA treatment (Fig. 2D) . The results showed that IFN-␥ was an absolute requirement for the occurrence of suppressive effects by CD8 ϩ DCs cotransferred with IL-12-primed CD8 Ϫ DCs. However, the effect was equally ablated by treatment of the tolerogenic fraction with 1-MT or Indo siRNA before DC cotransfer. This confirms that IDO is a major pharmacologic target of racemic 1-MT in our experimental setting of CD8 ϩ DC conditioning in vitro with IFN-␥.
Detection of transcriptional but not functional expression of kynurenine pathway enzymes in CD8 Ϫ DCs treated with IFN-␥
Using RT-PCR, we previously showed that IFN-␥ activates Indo transcription in both CD8 ϩ and CD8 Ϫ DCs, resulting in comparable expressions of IDO protein in the two subsets (21, 23) . In this 
Ϫ and CD8 ϩ DCs and extended the examination to a series of genes coding for enzymes downstream of IDO, namely Kmo (coding for kynurenine 3-monooxygenase), Kynu (kynureninase), and Haao (3-hydroxyanthranilate 3,4-dioxygenase) (Fig. 3A) . The results confirmed enhanced transcriptional activity of Indo by IFN-␥ in CD8
Ϫ DCs, to an extent comparable to CD8 ϩ counterparts. Similar to Indo albeit to a lesser extent, the expressions of Kmo, Kynu, and Haao were all enhanced by IFN-␥ in both DC subsets. Despite the increase in gene transcription, IFN-␥ induced little or no production of KYN and QUIN in CD8 Ϫ DCs (Fig. 3B) , possibly accounting for the failure of the recombinant cytokine to promote tolerogenic properties in this subset (21, 23, 35) . In contrast, in CD8
ϩ DCs, IFN-␥ resulted in early (5 h) production of KYN, followed by later (18 h) detection of high levels of QUIN. Collectively, these data indicated that DCs are endowed with the whole enzymatic machinery necessary for the production of one of the end products of the kynurenine pathway, QUIN. However, these data do not clarify whether the inability of IFN-␥ to activate the pathway in the CD8 Ϫ subset of DCs is due solely to an inefficient rate-limiting step (i.e., the one mediated by IDO) or to a combination of the latter with posttranscriptional regulation of downstream enzymes.
KYN conversion into QUIN occurs in CD8
Ϫ DCs, resulting in tolerogenic properties
We investigated whether the enzyme response induced by IFN-␥ downstream of IDO in CD8
Ϫ DCs is associated with the production of QUIN when the precursor KYN is added to the culture medium. We first validated the model by adding KYN to a culture of Indo siRNA-treated CD8 ϩ DCs and found that the addition of the external precursor was indeed associated with the production of QUIN when the cells had been exposed to IFN-␥ (Fig. 4A) . Similar to the latter cells, CD8
Ϫ DCs produced high levels of QUIN if cotreated with IFN-␥ and KYN. The ability of CD8 Ϫ DCs to release QUIN in response to IFN-␥ and the externally added precursor prompted us to investigate whether synthesis of QUIN was associated with the acquisition of properties typical of the tolerogenic CD8 ϩ DC subset. In the experimental setting illustrated above, we measured apoptosis of CD4 ϩ cells cultured with CD8 Ϫ DCs either untreated or treated with IFN-␥ and KYN, singly or in combination (Fig. 4B) . The results revealed an ability of the CD8 Ϫ DCs to induce apoptosis in ϳ25% of Th1 target cells upon coexposure to IFN-␥ and KYN. We also asked whether the CD8 Ϫ DCs conditioned by KYN and IFN-␥ treatment would be capable of suppressive properties in vivo when cotransferred with otherwise immunogenic DCs. In an experimental model system similar to that of Fig. 2D , P815AB-pulsed and IL-12-primed CD8 Ϫ DCs were injected in combination with 5% CD8
Ϫ DCs cotreated with a mixture of IFN-␥ and KYN, either alone or together with PNU 156561, a selective inhibitor of kynurenine 3-monooxygenase (Fig. 5A) . The results showed that the combined effects of IFN-␥ and KYN turned CD8 Ϫ DCs from immunogenic to suppressive, thus mimicking the behavior of the CD8 ϩ DC subset. However, inhibiting the conversion of KYN into 3-HK, and thus preventing synthesis of QUIN, abolished the onset of suppressive properties in the CD8 Ϫ DC fraction. Of interest, the mice sensitized with the DC population containing 5% IFN-␥/KYN-treated CD8 Ϫ DCs were not amenable to subsequent immunogenic priming to the peptide when performed 1 mo after the first exposure (Fig. 5B) . Again, this effect is similar to that observed with IFN-␥-treated CD8 ϩ DCs (35) and indicates the onset of an Ag-specific tolerant state. Taken together, these data suggest that even in the absence of functional IDO, kynurenine pathways enzymes, if activated by IFN-␥ in the presence of an appropriate precursor, catalyze the synthesis of QUIN, and the effect is associated with DC acquisition of tolerogenic properties.
IDO-competent DCs transfer tolerogenic potential across a cell-impermeable membrane
The finding that kynurenine pathway enzymes downstream of IDO can initiate tolerogenesis in DCs lacking functional IDO prompted us to investigate whether IDO-competent cells might turn otherwise immunogenic DCs into tolerogenic cells via soluble molecules. CD8
ϩ DCs were exposed overnight to IFN-␥, and CD8 Ϫ DCs were added to the lower chamber of a Transwell system. The CD8 ϩ cells had been treated with either negative control or Indospecific siRNAs. The CD8 Ϫ DCs were then recovered and assayed in vivo for their ability to suppress induction of skin test reactivity to P815AB (Fig. 6) . According to the experimental model described above, a minority fraction of conditioned CD8 Ϫ DCs was added to an IL-12-treated counterpart, and the mixture was transferred into recipients to be assayed at 2 wk for the development of skin test reactivity. The results showed that otherwise nontolerogenic CD8
Ϫ DCs became suppressive as a result of coculture in the Transwell system with CD8
ϩ DCs treated with negative control but not Indo siRNA. This result demonstrates that IDO-competent DCs can confer tolerogenic potential on cells lacking functional IDO by means of tryptophan catabolism and the production of soluble diffusible molecules.
Discussion
The kynurenine pathway is a major route of L-tryptophan catabolism, resulting in the production of nicotinamide adenine dinucleotide and other neuroactive (37, 38) and immunomodulatory (10) intermediates. Although all kynurenines are found in high concentration in urine, none of them has so far been assigned an important physiological function in peripheral organs. In the brain, the kynurenine pathway yields several intermediates, including the free radical generator 3-HK, the excitotoxic N-methyl-D-aspartate receptor agonist QUIN as well as its antagonist, kynurenic acid. Astrocytes, neurons, and microglia all express IDO, but only microglial cells are capable of producing substantial quantities of QUIN (39) . Although KYN can be produced in the brain to a ϩ DCs (10 6 ) were added to the upper chamber of a Transwell system, the bottom chambers of which contained an equal number of CD8 Ϫ DCs. rIFN-␥ was present in the cultures at 200 U/ml, and the CD8 ϩ DCs had been transfected with Indo siRNA or negative control (nc) siRNA. After 18 h, the recovered CD8 Ϫ DCs were pulsed with P815AB and added to a majority fraction (95%) of peptide-pulsed, IL-12-treated DCs. The cells were then transferred into recipient mice that were assayed at 2 wk for P815AB-specific skin test reactivity. The contents of the lower and upper chambers of the Transwell are indicated in the figure.
Compiled data from three experiments. ‫,ء‬ p Ͻ 0.0001 (experimental vs control footpads). Ϫ DCs was also exposed to 20 M PNU 156561, a selective inhibitor of kynurenine 3-monooxygenase. The cells were then transferred into recipient hosts. Mice were assayed for skin test reactivity on day 15 after cell transfer (A) or, alternatively, were treated on day 30 with an otherwise effective priming consisting of P815AB-pulsed CD8
Ϫ DCs, to be assayed for skin test reactivity on day 45 (B). Compiled data from three experiments. ‫,ء‬ p Ͻ 0.0001 (experimental vs control footpads).
moderate degree, the cerebral pathway is driven mainly by bloodborne KYN, which enters from the circulation using the large neutral amino acid transporter. In the brain, KYN is rapidly taken up by astrocytes and microglial cells, to be converted into end products that are then released extracellularly (37) .
In the periphery, the immunosuppressive pathway of tryptophan catabolism has been shown to contribute to successful pregnancy (1) and transplantation (2) , as well as to effective control of autoimmunity (3). We have proposed a model of transplantation tolerance that might apply to both transplantation and autoimmunity (10) . In this model, IFN-␥ acts on tolerogenic DCs to activate IDO, resulting in the onset of specific tolerance through the induction of tryptophan starvation and the production of immunomodulatory kynurenines. Extensive work in our as well as others' laboratories has subsequently shown that this model 1) accommodates the activity of regulatory T cells (Tregs) that, expressing surface CTLA-4, engage B7 coreceptor molecules on DCs and initiate the production of autocrine IFN-␥ (12, 30); 2) applies to different subsets of DCs, including plasmacytoid DCs (15, 26) ; and 3) suggests that the IDO mechanism is quite general in nature, in that, for example, not only DCs but also CD4 ϩ T cells (40) and neutrophils (7) respond to CTLA-4 engagement of their surface B7 molecules with the activation of IDO, depending on the release of autocrine IFN-␥.
Despite much evidence for such a general role of tryptophan catabolism as a mechanism of immunosurveillance (17), there are several mechanistic features of the pathway that await further clarification (19) . Among these are the relative contributions of IDO and the remainder pathway enzymes to immunosuppression (41), as well as the possible function of specific kynurenines as inducers or mediators of immunoregulation (18, 33, (42) (43) (44) . In this study, we have provided evidence that 1) IDO is the major relevant target of pharmacologic inhibition of the kynurenine pathway when racemic 1-MT is used as an enzyme inhibitor; 2) DCs express the entire metabolic machinery necessary for synthesis of QUIN; 3) IFN-␥ enhances the transcriptional expression of all these enzymes, which may in fact respond as a coordinately regulated cluster of genes (45); yet, posttranslational inactivation of IDO occurs in nontolerogenic CD8 Ϫ DCs, and this prevents the action of enzymes consequent to IDO function; and 4) bypassing the IDOassociated blockade by the addition of a downstream QUIN precursor initiates the pathway and leads to the onset of suppressive properties in CD8 Ϫ DCs treated with IFN-␥. Human macrophages are endowed with the ability to convert tryptophan to QUIN (46, 47) ; yet, no information was previously available regarding the functional expression of kynurenine pathway enzymes other than IDO in human or murine DCs. We found that the splenic CD8 ϩ subset of murine DCs could be induced by IFN-␥ to release high levels of QUIN. Despite functional lack of the pathway regulatory enzyme IDO in CD8 Ϫ DCs, these cells could nevertheless be induced by IFN-␥ to produce QUIN in the presence of KYN, a downstream precursor of the end product. Activation of the pathway was accompanied by the appearance of tolerogenic properties in vivo. Thus, the current study may be the first to demonstrate the presence of a functional kynurenine pathway in murine DCs and, interestingly, to specifically associate the tolerogenic phenotype with the function of a coordinately regulated set of enzymes, as observed upon treatment with IFN-␥. In addition, similar to what was observed with astrocytes and microglial cells (37) , our current data demonstrate that KYN is taken up by DCs. The kynurenine 3-monooxygenase-dependent conversion of KYN into QUIN by DCs further demonstrates that specific intracellular metabolism of kynurenines occurs in those cells. Of interest in this regard, we have also found that similar to KYN, synthetic 3-HAA is also taken up by DCs, resulting in the production of QUIN (data not shown).
DCs have several modes at their disposal to mediate tolerogenic functions, and metabolic pathways of immune regulation are but one possibility (48) . A distinctive feature of tryptophan catabolism as an effector mechanism of suppression is that its function is compatible with a directive role of Tregs in orchestrating peripheral tolerance (30) . We have previously shown that the default immunogenic or tolerogenic program of Ag presentation by DC subsets is highly flexible, and that otherwise immunogenic DCs can be rendered tolerogenic by the actions of inhibitory ligands expressed by T cells (2, 22, 26, 27) . Unlike soluble or cell-bound CTLA-4, IFN-␥ is unable per se to induce functional IDO expression in CD8 Ϫ DCs (21) . Our current data demonstrate that, in the presence of IFN-␥, CD8
Ϫ DCs can be rendered tolerogenic by the nearby production of kynurenines that are taken up by the cells and then metabolized to downstream products of the pathway. This mechanism is qualitatively different from that of CTLA-4, which acts on CD8 Ϫ DCs to activate IDO, making it functionally responsive to IFN-␥ up-regulation (21) . On the one hand, the bulk of these data demonstrates that tryptophan consumption may not always be an absolute requirement for the DCs to exert suppressive properties. On the other hand, it is possible that, to meet the needs of flexibility and redundancy, the paracrine production of kynurenines is exploited by IDO-competent DCs to convert DCs that are not competent to a tolerogenic phenotype.
A model of cross-talk of DCs and T cells in tryptophan catabolism within an IFN-␥-rich environment is illustrated in Fig. 7 . The model, far from detracting from the role of tryptophan starvation in mediating specific effects of the IDO mechanism (16), reinforces the concept that tryptophan deprivation and tryptophan FIGURE 7. A model of cross-talk of DCs and T cells in tryptophan catabolism. In local tissue microenvironments, the activity of IDO competent DCs (IDO ϩ ) driven by IFN-␥ will result in the sustained production of kynurenines (Kyn). These, in turn, could recruit other cell types to the regulatory response, including DCs in which the function of IDO, but not other kynurenine pathway enzymes, is inhibited posttranslationally (IDO Ϫ ). The combined effects of tryptophan (Trp) starvation (16) , caused by IDO ϩ DCs, and the high kynurenine production, resulting from the actions of IDO ϩ and IDO Ϫ DCs, is expected to induce a great variety of effects on target T cells (18, 33, 44) and other cell types (42, 43) . Tregs would have a crucial role in establishing an IFN-␥-rich environment, either via CTLA-4/B7-dependent interaction with DCs (30) or by direct production of the cytokine (49) . Because the combined effects of tryptophan starvation and tryptophan catabolites include the induction of a regulatory phenotype in naive CD4
ϩ T cells (51), an IDO-based positive feedback loop might be locally operative, resulting in Treg generation by Tregs (dotted line).
catabolites may act singly or in combination to establish a regulatory environment most suitable to the control of local inflammatory or systemic T cell-mediated responses. The model also emphasizes the likely dual role of tryptophan catabolism both as an effector system (30, 49) and an inducer of Treg activity (7, 44, 50, 51) . Because 1-MT has been shown to act synergistically with cytoreductive chemotherapy in an experimental tumor setting (9), the identification of proper enzyme targets for pharmacologic inhibition of the kynurenine pathway may pave the way to improved strategies of antitumor chemotherapy (13) . More generally, understanding the molecular mechanisms that preside over control of IDO expression by DCs may provide new opportunities for designing ways to induce or abrogate tolerance in physiopathologic conditions (21, 25, 52) .
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